Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Vor Biopharma Inc

Company price
19.19 USD 0.67 ( 3.62%)
Last update at 2026-11-20T21:00:00Z
VOLUME
1536489
Market Cap
1320.50M
P/E
0.13

Momentum Score

…

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
17.99
Low
19.91
High
52 Week Price Range
6.50
Low
49.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Vor Biopharma is a clinical-stage cell therapy company developing engineered hematopoietic stem cell products intended to protect normal bone marrow while enabling successive targeted leukemia treatments; its lead program VOR33 targets resistance to CD33-directed agents. Long-term growth may be driven by clinical progress across its HSC editing platform, expansion to additional oncology targets, and potential partnerships or licensing to scale manufacturing, and investors may find the differentiated approach to combining cell therapy with targeted agents of interest.

The most important investment risks are clinical and regulatory uncertainty for first-in-human HSC editing programs, complex and costly manufacturing and scaling challenges, high cash burn, and the likely need for additional financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
18.52
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.02
ROE
-125.43%
Net Debt
-393.49M
ROCE
-158.55%
Diluted EPS TTM
174.71

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -695.98M -116.91M -117.86M -92.09M -68.90M
Net income -695.98M -116.91M -117.86M -90.77M -68.78M
Selling general administrative 50.11M 27.88M 31.72M 28.87M 21.49M
Selling and marketing expenses - - 3.49M - -
Gross profit - -3.53M -3.49M - -
Reconciled depreciation 2.89M 3.53M 3.23M 2.52M 1.43M
Ebit -695.98M -116.91M -117.86M -93.42M -69.02M
Ebitda -693.09M -113.39M -114.37M -90.89M -67.58M
Depreciation and amortization 2.89M 3.53M 3.49M 2.52M 1.43M
Non operating income net other - - - 1.32M 0.12M
Operating income -371.64M -121.19M -126.04M -93.42M -69.02M
Other operating expenses 371.64M 121.19M 126.04M 93.42M 69.02M
Interest expense - - - 1.32M 1.55M
Interest income 5.87M 4.27M 7.12M 1.32M 0.12M
Net interest income 5.87M 4.27M 7.12M 1.32M 0.12M
Income tax expense - - - -1.32M -0.12M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 371.64M 121.19M 122.54M 93.42M 69.02M
Cost of revenue - 3.53M 3.49M - -
Total other income expense net -324.34M 4.27M 8.17M 1.32M 0.12M
Net income from continuing ops -695.98M -116.91M -115.51M -92.09M -68.90M
Net income applicable to common shares - - - -92.09M -70.13M
Preferred stock and other adjustments - - - - 1.23M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 464.13M 142.89M 209.83M 299.37M 242.59M
Other current assets 2.90M 4.58M 3.63M 2.34M 2.09M
Total liab 628.44M 46.23M 59.10M 48.76M 26.33M
Total stockholder equity -164.31M 96.66M 150.72M 250.61M 216.26M
Other current liab 19.76M 12.89M 10.93M 8.07M 0.43M
Common stock 0.02M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.02M 0.01M 0.01M 0.01M 0.00M
Retained earnings -1152.97M -456.99M -340.08M -222.22M -130.12M
Other assets - - - 5.34M 5.67M
Cash 396.49M 81.95M 31.36M 57.71M 119.80M
Total current liabilities 25.17M 18.61M 15.57M 13.12M 10.15M
Current deferred revenue - - - - 6.33M
Net debt -393.49M -50.12M 4.30M -18.79M -101.79M
Short term debt 0.28M 4.21M 3.83M 3.27M 1.84M
Short long term debt total 3.00M 31.83M 35.66M 38.91M 18.01M
Other stockholder equity 988.60M 553.62M 490.87M 473.59M 346.38M
Property plant equipment - - - 12.63M 6.85M
Total current assets 458.11M 96.51M 140.80M 236.95M 214.40M
Net tangible assets - - - 250.61M 216.26M
Short term investments 58.72M 9.98M 105.81M 172.54M 87.67M
Accounts payable 5.13M 1.50M 0.81M 1.77M 1.54M
Accumulated other comprehensive income 0.04M 0.02M -0.08M -0.77M -242.59M
Common stock total equity - - - 0.01M 0.00M
Retained earnings total equity - - - -222.22M -130.12M
Non currrent assets other 2.55M 4.80M 4.81M 5.34M 5.67M
Non current assets total 6.02M 46.38M 69.03M 62.42M 28.19M
Capital lease obligations 3.00M 31.83M 35.66M 38.91M 18.01M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -48.66M 96.86M -36.36M -85.63M -87.76M
Change to liabilities - - - 1.11M 0.41M
Total cashflows from investing activities -48.80M 96.86M 71.01M -94.09M -91.65M
Total cash from financing activities 503.81M 53.39M 2.94M 117.14M 232.91M
Change to operating activities - - - -13.81M -9.59M
Net income -695.98M -116.91M -117.86M -92.09M -68.90M
Change in cash 312.29M 50.59M -26.35M -62.09M 72.12M
Begin period cash flow 84.36M 33.77M 60.12M 122.21M 50.10M
End period cash flow 396.65M 84.36M 33.77M 60.12M 122.21M
Total cash from operating activities -142.71M -99.66M -100.29M -85.14M -69.14M
Issuance of capital stock 328.21M 55.83M 116.22M 115.97M 234.57M
Depreciation 2.89M 3.53M 3.49M 2.52M 1.43M
Other cashflows from investing activities 0.80M - - - -
Sale purchase of stock - - -1.19M 4.45M 187.54M
Other cashflows from financing activities -1.32M -2.43M -1.64M 1.17M 43.71M
Change to netincome - - - 10.68M 4.49M
Capital expenditures 0.94M 0.23M 1.07M 8.46M 3.89M
Cash flows other operating - - - -7.37M -6.57M
Cash and cash equivalents changes - - - -62.09M 72.12M
Change in working capital 10.21M 0.01M 0.65M -12.69M -9.19M
Stock based compensation 18.91M 9.85M 13.36M 10.70M 4.32M
Other non cash items 521.26M 3.87M 0.07M 6.42M 3.19M
Free cash flow -143.65M -99.89M -101.36M -93.61M -73.04M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
VOR
Vor Biopharma Inc
0.67
3.62%
19.19 0.13 - - 0.66 -3.09
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Vor Biopharma Inc

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

500 Boylston Street, Boston, MA, United States, 02116

617 655 6580

76

Name Title Year Born
Dr. Robert Ang M.B.A., M.D., MBBS Pres, CEO & Director 1975
Dr. Tirtha Chakraborty Ph.D. Chief Scientific Officer 1973
Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. Scientific Founder & Chairman of Scientific Advisory Board 1971
Dr. Nathan D. Jorgensen M.B.A., Ph.D. Chief Financial Officer 1977
Ms. Tania Philipp Chief People Officer 1972
Dr. Robert G. Pietrusko Pharm.D., Pharm. D. Chief Regulatory & Quality Officer 1948
Mr. John C. King M.B.A. Chief Commercial Officer 1976
Dr. Veit Schmelmer Ph.D. Sr. VP of Program & Alliance Management NA
Dr. Eyal C. Attar M.D. Chief Medical Officer 1971
Dr. Robert Ang M.B.A., M.D., MBBS President, CEO & Director 1975

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…